medwireNews : ESMO’s Clinical Practice Guideline for the management of metastatic breast cancer is now available and published in the Annals of Oncology .

Women with hormone receptor-positive, HER2-negative metastatic breast cancer derive a significant progression-free survival benefit from the addition of alisertib to paclitaxel, indicate phase 2 trial findings.

medwireNews : The US FDA has expanded the indication of olaparib to include metastatic breast cancer patients with a deleterious or suspected deleterious germline BRCA mutation.

Women receiving first-line pertuzumab or second-line trastuzumab emtansine for HER2-positive metastatic breast cancer have lower than expected survival times in clinical practice when compared with pivotal trials, researchers report.

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

Beneficial outcomes with pembrolizumab plus chemotherapy persist with different types of chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer, exploratory analysis of the KEYNOTE-355 trial suggests.

The anti-HER2 monoclonal antibody margetuximab , given alongside chemotherapy, is indicated for adults with metastatic HER2-positive breast cancer who have received at least two previous HER2-directed therapies, of which one must have been given in the metastatic setting.

Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative, endocrine-sensitive, metastatic breast cancer, shows the phase 2 FLIPPER trial.

Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).

Women with hormone receptor-positive, HER2-positive locally advanced, metastatic, or recurrent breast cancer might benefit from a third- or later-line regimen of the CDK4/6 inhibitor abemaciclib in combination with trastuzumab and fulvestrant, findings from the phase 2 monarcHER trial suggests.

Other indications include treatment in combination with chemotherapy for metastatic colorectal cancer, metastatic breast cancer, and recurrent or metastatic carcinoma of the cervix.

Here we provide top-line summaries of results from three phase III breast cancer trials, evaluating nab-paclitaxel and a trastuzumab biosimilar in the nonmetastatic HER2-negative and -positive settings, respectively, and quality of life with the addition of palbociclib in the advanced or metastatic setting.